{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000039","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-07-29T15:38:46+00:00","discovered_at":"2026-07-29T15:40:00.379714+00:00","generated_at":"2026-07-29T15:40:06.195382+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AbCellera announces collaboration with Vertex to develop T-cell engagers; receives $281M upfront","bullets":["Collaboration with Vertex (VRTX) to discover multispecific T-cell engagers for autoimmune diseases and other conditions.","AbCellera leads discovery and early development; Vertex funds all R&D costs and holds commercialization rights.","AbCellera receives $281 million in total upfront payments, plus preclinical, development, regulatory, and commercial milestones and tiered royalties.","AbCellera may also perform cell line development, process development, and clinical manufacturing through Phase 1 for any program."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000039","json":"https://secwatch.observer/filing/0001703057-26-000039.json","markdown":"https://secwatch.observer/filing/0001703057-26-000039.md","text":"https://secwatch.observer/filing/0001703057-26-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/0001703057-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000039/abcl-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T15:40:06.195382+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}